NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Gene Therapy Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Breast Cancer



Report summarizes breast cancer study findings from D.O. Croci and co-researchers



December 18th, 2008

According to a study from Buenos Aires, Argentina, "Survivin is recognized as an attractive target in cancer therapy because of its selective overexpression in the majority of tumors. Upregulated expression of this protein correlates with increased tumor grade, recurrence risk and decreased cancer patients survival."

"In this study, we assessed the efficacy of two survivin-specific small interfering RNA (siRNA) constructs to inhibit T47D human breast cancer cell growth. After siRNA transfection, T47D cells showed a significant reduction in proliferation and survival exhibiting clear signs of apoptosis. pSil_1 that targeted exon 1 exhibited a stronger inhibitory effect...


Source: Gene Therapy Weekly (2008-12-18)

NewsRx Passes
Advertisement
More Articles

Related Topics

------------------------
Security by Verisign PR Login